Welcome to our dedicated page for Pharvaris N.V. SEC filings (Ticker: PHVS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Pharvaris N.V. filings document foreign private issuer disclosures for a late-stage biopharmaceutical company developing oral bradykinin B2 receptor antagonists. Form 6-K reports furnish financial results, business updates, investor presentations, clinical-study updates, annual general meeting voting results and materials incorporated by reference into Form F-3 and Form S-8 registration statements.
The filing record also covers capital-structure activity involving ordinary shares and pre-funded warrants, registration rights agreements, underwriting documents, share-based compensation and governance matters. These disclosures frame Pharvaris' development-stage operating expenses, financing activity, shareholder approvals and formal reporting obligations as a Nasdaq-listed foreign private issuer.
Pharvaris N.V. (PHVS) disclosed that officer Anne Simone Lesage has filed a Rule 144 notice to sell 30,000 shares of common stock, expected to be issued from a stock option exercise and sold for cash through Morgan Stanley Smith Barney LLC on September 10, 2026 on NASDAQ.
The notice also lists prior common-share sales during the three months ended June 30, 2026 by Anne Lesage and Graymatters Consulting B.V., with several transactions ranging from 2,300 to 30,703 shares and reported dollar amounts for each sale.
Pharvaris N.V. (PHVS) is the issuer for which a Form 144 notice has been filed by director Robert R. Glassman, indicating an intended sale of common shares under Rule 144. The filing lists a proposed sale of 8,000 common shares through Morgan Stanley Smith Barney LLC, in connection with a stock option exercise dated September 9, 2026, with an aggregate value of $300,396.00 and listing on NASDAQ.
Pharvaris N.V. (PHVS) reported that President Lu Peng exercised options to acquire 15,000 shares of Common Stock at $2.59 per share on September 8, 2026 and, in a related cashless transaction under a Rule 10b5-1 trading plan, sold 15,000 shares at a weighted average of $40.6756 per share. Following these transactions, options to purchase 43,308 shares at $2.59 remain outstanding, expiring on February 3, 2030.
Pharvaris N.V. (PHVS) has an officer, Peng Lu, who has filed a notice of proposed sale of common shares under Rule 144. The notice covers 30,000 common shares, to be obtained through the exercise of stock options for cash on or about September 8, 2026.
The shares listed for potential sale have an aggregate market value of $1,057,500, and the notice references 68,072,885 common shares outstanding. The officer also reports prior Rule 10b5-1 plan sales of Pharvaris common stock in the past three months.
Pharvaris N.V. (PHVS) reported topline Phase 3 CHAPTER-3 results for deucrictibant XR 40 mg once daily as long-term prophylaxis for hereditary angioedema (HAE). In 85 participants randomized 2:1 against placebo, deucrictibant XR achieved the primary endpoint with an 83% reduction in time‑normalized HAE attack rate versus placebo (p<0.0001), and an 87% reduction in the HAE Type 1/2 subgroup.
All key secondary efficacy endpoints were met with statistically significant results, including a 23.53‑point greater improvement versus placebo in the Angioedema Quality of Life total score at Week 24, indicating meaningful quality-of-life benefit. Attack reduction was observed within one week and sustained over 24 weeks. Deucrictibant XR was reported as well tolerated: any treatment‑emergent adverse events occurred in 76.4% of active‑treated participants versus 56.7% on placebo, with no treatment‑related serious adverse events and low discontinuation rates in both groups. Pharvaris highlights these data alongside prior positive on‑demand studies and notes that a U.S. PDUFA goal date for on‑demand deucrictibant is April 23, 2027 and an NDA submission for prophylaxis is anticipated in the first half of 2027.
Pharvaris N.V. (PHVS) reported positive topline data from its CHAPTER-3 pivotal Phase 3 study of oral deucrictibant XR tablets for prophylaxis of hereditary angioedema (HAE) attacks. The trial met its primary endpoint, showing an 83% reduction in mean monthly HAE attack rate versus placebo across all three HAE types, with p<0.0001.
In participants with HAE Type 1 or Type 2, deucrictibant XR reduced attack rates by 87% versus placebo, and all secondary efficacy endpoints were met with statistical significance. Deucrictibant XR was described as well tolerated, with no treatment-related serious adverse events and only one discontinuation per arm due to adverse events. Pharvaris plans to use CHAPTER-3 data as the basis for marketing authorization applications, including a planned New Drug Application for prophylaxis of bradykinin-mediated angioedema attacks in the first half of 2027, while continuing related late-stage programs such as CHAPTER-4 and the CREAATE Phase 3 study in AAE-C1INH.
Pharvaris N.V. (PHVS) reported that Chief Executive Officer Berndt Modig sold 2,292 shares of common stock on 2026-08-14 at an average price of $34.7669 per share. The shares were acquired upon vesting of restricted stock units and the sale was made pursuant to a Rule 10b5-1 trading plan. Following this transaction, Modig holds 130,625 shares directly and 950,000 shares indirectly through Schoodic Management BV, an entity he controls.
Pharvaris N.V. has a significant shareholder group led by General Atlantic entities, which report beneficial ownership of Pharvaris ordinary shares. General Atlantic PH B.V. holds 5,359,727 ordinary shares, representing 7.6% of Pharvaris’ outstanding ordinary shares as of August 14, 2026. All listed General Atlantic funds and coinvestment vehicles are deemed to share voting and dispositive power over these shares through their control structure and general partner relationships.
The ownership percentages are based on 70,204,506 ordinary shares outstanding as of June 30, 2026, as reported in Pharvaris’ unaudited interim financial statements filed on a Form 6-K. This amendment updates the group’s Schedule 13G disclosure and confirms that General Atlantic PH B.V. is the sole record holder within the group.
Berndt B.A.E. Modig plans to sell 2,292 shares of PHVS common stock through Morgan Stanley Smith Barney LLC Executive Financial Services, with an aggregate market value of 78,019.68, listed on NASDAQ. The shares relate to Restricted Stock Units dated 08/11/2026 and issued by the company.
The disclosure also lists prior Rule 10b5-1 sales of PHVS common stock by Modig over the past three months: 2,292 shares for 80,154.45 on 07/13/2026, 2,291 shares for 71,172.89 on 06/15/2026, and 2,292 shares for 68,581.68 on 05/15/2026.
Pharvaris N.V. President Lu Peng reported two code F transactions involving company common stock. On 2026-08-12, 117 shares were withheld at $34.42 per share, and on 2026-08-11, 109 shares were withheld at $34.84 per share. Footnote disclosure states these 226 shares were retained by the issuer to satisfy tax withholding obligations upon the vesting of restricted stock units, rather than being sold in open-market transactions. The filing indicates these events were not executed under a Rule 10b5-1 trading plan.